Biotech Boom, Drug Lag: Japan's Innovation Paradox
Japan has many of the ingredients of a world-class biotechnology ecosystem: leading scientific research, Nobel Prize-winning discoveries, and growing investment. Yet many innovative medicines reach Japanese patients later than in other markets, and some never launch at all.
So what explains the gap?
In this special Tokyo episode of the Making Medicine Podcast, host John Stanford is joined by Michael Gutbrod, Principal at Santé Ventures, and Marian Nakada, former Vice President of Venture Investments at Johnson & Johnson Development Innovation, for a conversation about Japan’s innovation…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.